MovDisordV3, Main, Exploration, bibRecord, 003691

Trial of subtherapeutic pergolide in de novo Parkinson's disease

Identifieur interne : 003691 ( Main/Exploration ); précédent : 003690; suivant : 003692

Trial of subtherapeutic pergolide in de novo Parkinson's disease

Auteurs : Katherine Grosset [Royaume-Uni] ; Donald Grosset [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]

Source :

Movement Disorders [ 0885-3185 ] ; 2005-03.

RBID : ISTEX:2DCDAC6475C77863690B5706D941F6E193C111FD

English descriptors

KwdEn :
- Adult, Aged, Dopamine Agonists (therapeutic use), Double-Blind Method, Female, Humans, Male, Middle Aged, Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson's disease, Pergolide (therapeutic use), Prospective Studies, delaying levodopa, neuroprotective, subtherapeutic pergolide.
MESH :
- chemical , therapeutic use : Dopamine Agonists, Pergolide.
- diagnosis : Parkinson Disease.
- drug therapy : Parkinson Disease.
- Adult, Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Prospective Studies.

Abstract

The effect of pergolide 25 μg twice daily on levodopa initiation was assessed in a randomized, placebo‐controlled, parallel group, double‐blind multicenter trial in 106 untreated early Parkinson's disease patients. The primary endpoint of mean time until levodopa was 520 days (95% confidence interval [CI], 422–618 days) for pergolide versus 434 days (95% CI, 358–609 days) for placebo. However, this increase of 86 days for pergolide was not statistically significant. The wash‐in effect of pergolide was significant at 6 weeks (change in mean Unified Parkinson's Disease Rating Scale [UPDRS] 2 and 3 was −0.1 [95% CI, −1.4 to 1.3] for pergolide vs. 2.2 [95% CI, 1.1–3.3] for placebo). At termination, the change from baseline in mean UPDRS 2 and 3 score was 11.4 (95% CI, 8.8–14) for pergolide and 14.6 (95% CI, 12–17.2) for placebo (P = 0.08). There was no significant change in UPDRS 2 and 3 for the 83 patients achieving the planned 4‐week washout at termination (pergolide 1.2 [95% CI, −0.8 to 3.2] vs. placebo 0.0 [95% CI, −1.6 to 1.6]. Adverse events were infrequent and occurred equally for pergolide and placebo. The study shows no evidence of a neuroprotective effect but indicates a mild symptomatic benefit from pergolide at a dose normally considered subtherapeutic. © 2004 Movement Disorder Society

Url:

https://api.istex.fr/document/2DCDAC6475C77863690B5706D941F6E193C111FD/fulltext/pdf

DOI: 10.1002/mds.20361

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Trial of subtherapeutic pergolide in de novo Parkinson's disease</title>
<author><name sortKey="Grosset, Katherine" sort="Grosset, Katherine" uniqKey="Grosset K" first="Katherine" last="Grosset">Katherine Grosset</name>
</author>
<author><name sortKey="Grosset, Donald" sort="Grosset, Donald" uniqKey="Grosset D" first="Donald" last="Grosset">Donald Grosset</name>
</author>
<author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees (neurologue)</name>
<affiliation><country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName>National Hospital for Neurology and Neurosurgery</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:2DCDAC6475C77863690B5706D941F6E193C111FD</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1002/mds.20361</idno>
<idno type="url">https://api.istex.fr/document/2DCDAC6475C77863690B5706D941F6E193C111FD/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002862</idno>
<idno type="wicri:Area/Istex/Curation">002862</idno>
<idno type="wicri:Area/Istex/Checkpoint">002097</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Grosset K:trial:of:subtherapeutic</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15580607</idno>
<idno type="wicri:Area/PubMed/Corpus">003195</idno>
<idno type="wicri:Area/PubMed/Curation">003195</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002F22</idno>
<idno type="wicri:Area/Ncbi/Merge">001106</idno>
<idno type="wicri:Area/Ncbi/Curation">001106</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001106</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Grosset K:trial:of:subtherapeutic</idno>
<idno type="wicri:Area/Main/Merge">004D74</idno>
<idno type="wicri:Area/Main/Curation">003691</idno>
<idno type="wicri:Area/Main/Exploration">003691</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Trial of subtherapeutic pergolide in de novo Parkinson's disease</title>
<author><name sortKey="Grosset, Katherine" sort="Grosset, Katherine" uniqKey="Grosset K" first="Katherine" last="Grosset">Katherine Grosset</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Neurological Sciences, Southern General Hospital, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Grosset, Donald" sort="Grosset, Donald" uniqKey="Grosset D" first="Donald" last="Grosset">Donald Grosset</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Institute of Neurological Sciences, Southern General Hospital, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees (neurologue)</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>University College London, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName>National Hospital for Neurology and Neurosurgery</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2005-03">2005-03</date>
<biblScope unit="vol">20</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="363">363</biblScope>
<biblScope unit="page" to="366">366</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">2DCDAC6475C77863690B5706D941F6E193C111FD</idno>
<idno type="DOI">10.1002/mds.20361</idno>
<idno type="ArticleID">MDS20361</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (diagnosis)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson's disease</term>
<term>Pergolide (therapeutic use)</term>
<term>Prospective Studies</term>
<term>delaying levodopa</term>
<term>neuroprotective</term>
<term>subtherapeutic pergolide</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agonists</term>
<term>Pergolide</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Prospective Studies</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The effect of pergolide 25 μg twice daily on levodopa initiation was assessed in a randomized, placebo‐controlled, parallel group, double‐blind multicenter trial in 106 untreated early Parkinson's disease patients. The primary endpoint of mean time until levodopa was 520 days (95% confidence interval [CI], 422–618 days) for pergolide versus 434 days (95% CI, 358–609 days) for placebo. However, this increase of 86 days for pergolide was not statistically significant. The wash‐in effect of pergolide was significant at 6 weeks (change in mean Unified Parkinson's Disease Rating Scale [UPDRS] 2 and 3 was −0.1 [95% CI, −1.4 to 1.3] for pergolide vs. 2.2 [95% CI, 1.1–3.3] for placebo). At termination, the change from baseline in mean UPDRS 2 and 3 score was 11.4 (95% CI, 8.8–14) for pergolide and 14.6 (95% CI, 12–17.2) for placebo (P = 0.08). There was no significant change in UPDRS 2 and 3 for the 83 patients achieving the planned 4‐week washout at termination (pergolide 1.2 [95% CI, −0.8 to 3.2] vs. placebo 0.0 [95% CI, −1.6 to 1.6]. Adverse events were infrequent and occurred equally for pergolide and placebo. The study shows no evidence of a neuroprotective effect but indicates a mild symptomatic benefit from pergolide at a dose normally considered subtherapeutic. © 2004 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
</region>
<settlement><li>Londres</li>
</settlement>
<orgName><li>National Hospital for Neurology and Neurosurgery</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><noRegion><name sortKey="Grosset, Katherine" sort="Grosset, Katherine" uniqKey="Grosset K" first="Katherine" last="Grosset">Katherine Grosset</name>
</noRegion>
<name sortKey="Grosset, Donald" sort="Grosset, Donald" uniqKey="Grosset D" first="Donald" last="Grosset">Donald Grosset</name>
<name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees (neurologue)</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003691 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003691 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:2DCDAC6475C77863690B5706D941F6E193C111FD
   |texte=   Trial of subtherapeutic pergolide in de novo Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Trial of subtherapeutic pergolide in de novo Parkinson's disease

Trial of subtherapeutic pergolide in de novo Parkinson's disease

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.